Titre :

Bortezomib, melphalan, and dexamethasone for light-chain amyloidosis

Auteur(s) :

Kastritis, Efstathios [Auteur]
National and Kapodistrian University of Athens [NKUA]
Leleu, Xavier [Auteur]
Hôpital Claude Huriez [Lille]
Arnulf, Bertrand [Auteur]
Hopital Saint-Louis [AP-HP] [AP-HP]
Zamagni, Elena [Auteur]
Alma Mater Studiorum Università di Bologna = University of Bologna [UNIBO]
Cibeira, Maria Teresa [Auteur]
Kwok, Fiona [Auteur]
Westmead Hospital [Sydney]
Mollee, Peter [Auteur]
Princess Alexandra Hospital, Brisbane
Hajek, Roman [Auteur]
Ostravská univerzita / University of Ostrava
Moreau, Philippe [Auteur]
Hôtel-Dieu de Nantes
Jaccard, Arnaud [Auteur]
CHU Limoges
Schonland, Stefan O. [Auteur]
University of Heidelberg, Medical Faculty
Filshie, Robin [Auteur]
St. Vincent's Hospital, Sydney
Nicolas-Virelizier, Emmanuelle [Auteur]
Centre Léon Bérard [Lyon]
Augustson, Bradley [Auteur]
Mateos, Maria-Victoria [Auteur]
Universidad de Salamanca [España] = University of Salamanca [Spain]
Wechalekar, Ashutosh [Auteur]
Hachulla, Eric [Auteur]
Institute for Translational Research in Inflammation - U 1286 [INFINITE]
Milani, Paolo [Auteur]
Dimopoulos, Meletios A. [Auteur]
University of Athens Medical School [Athens]
Fermand, Jean-Paul [Auteur]
Hôpital Saint-Louis
Foli, Andrea [Auteur]
Gavriatopoulou, Maria [Auteur]
University of Athens Medical School [Athens]
Klersy, Catherine [Auteur]
Palumbo, Antonio [Auteur]
Università degli studi di Torino = University of Turin [UNITO]
Sonneveld, Pieter [Auteur]
Erasmus University Medical Center [Rotterdam] [Erasmus MC]
Johnsen, Hans Erik [Auteur]
Aalborg University [Denmark] [AAU]
Merlini, Giampaolo [Auteur]
Università degli Studi di Pavia [Italia] = University of Pavia [Italy] = Université de Pavie [Italie] [UNIPV]
Palladini, Giovanni [Auteur]
Università degli Studi di Pavia [Italia] = University of Pavia [Italy] = Université de Pavie [Italie] [UNIPV]

Titre de la revue :

Journal of clinical oncology . official journal of the American Society of Clinical Oncology

Nom court de la revue :

J. Clin. Oncol.

Pagination :

JCO2001285

Date de publication :

2020-07-30

ISSN :

1527-7755

Discipline(s) HAL :

Sciences du Vivant [q-bio]

Résumé en anglais : [en]

Oral melphalan and dexamethasone (MDex) were considered a standard of care in light-chain (AL) amyloidosis. In the past decade, bortezomib has been increasingly used in combination with alkylating agents and dexamethasone. ...
Lire la suite >Oral melphalan and dexamethasone (MDex) were considered a standard of care in light-chain (AL) amyloidosis. In the past decade, bortezomib has been increasingly used in combination with alkylating agents and dexamethasone. We prospectively compared the efficacy and safety of MDex and MDex with the addition of bortezomib (BMDex). This was a phase III, multicenter, randomized, open-label trial. Patients were stratified according to cardiac stage. Patients with advanced cardiac stage (stage IIIb) amyloidosis were not eligible. The primary end point was hematologic response rate at 3 months. This trial is registered with ClinicalTrials.gov identifier NCT01277016. A total of 109 patients, 53 in the BMDex and 56 in the MDex group, received ≥ 1 dose of therapy (from January 2011 to February 2016). Hematologic response rate at 3 months was higher in the BMDex arm (79% vPv BMDex improved hematologic response rate and overall survival. To our knowledge, this is the first time a controlled study has demonstrated a survival advantage in AL amyloidosis. BMDex should be considered a new standard of care for AL amyloidosis.Lire moins >

Langue :

Anglais

Audience :

Internationale

Vulgarisation :

Non

Établissement(s) :

CHU Lille
Inserm
Université de Lille

Collections :

• Institut de Recherche Translationnelle sur l'Inflammation (INFINITE) - U1286

Date de dépôt :

2021-07-06T12:45:52Z
2024-03-27T12:50:21Z